EMA experts recommend risk reduction measures for Servier, Amgen drug; Sinking ruble hurts pharmas in Russia;

@FiercePharma: FDA tightens reins on equine compounding companies. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI Friday: Fresenius Russian partnership tanks even as Russian tanks spotted rolling into Ukraine. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Eisai 'speechless' after another Fycompa price smack-down from Germany. More | Follow @CarlyHFierce

> EMA experts have recommended measures to reduce the risks associated with a heart drug from Servier and Amgen ($AMGN). Report

> A dropping ruble is dragging down drugmakers that lean on Russian business. Report

> Belgian pharma UCB says it'll reach its target of a 30% core profit margin one year later than expected now that it's agreed to sell its generics business to two private equity firms for $1.53 billion. More

> Merck ($MRK) has signed a Januvia patient pact with pharmacy chain Numark. More

> Sanofi ($SNY) has launched its pediatric vaccine, Shan5, in India. Report

> Sun Pharma's shares hit their all-time high after unit Taro Pharmaceutical's quarterly profit grew by 49% to a record $143 million. Report

> Caverion is providing building systems for Baxter ($BAX) in Austria. More

Medical Device News

@FierceMedDev: ICYMI: Power morcellation ban unlikely, but other FDA restrictions coming soon; includes email to FDA obtained by FMD. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: The new AstraZeneca, University of Manchester center for drug delivery becomes operational in February. More | Follow @VarunSaxena2

> Microsoft 3-D audio system helps the visually impaired navigate more easily. Story

> Device for minimally invasive treatment of enlarged prostate gains CMS reimbursement. Article

Biotech News

@FierceBiotech: Biotech upstart Sage sees early efficacy for rare brain seizure drug. More | Follow @FierceBiotech

@JohnCFierce: From FierceBiotechResearch: Genentech R&D team fixes a flawed approach to Alzheimer's. Story | Follow @JohnCFierce

> Battered ArQule shares bump up on badly needed positive data for tivantinib. Article

> Fledgling Ziarco grabs a $33M transatlantic round for PhII atopic dermatitis drug. Story

> J&J chief hints at unease in China, but plots new buyouts. Item

> Merck's hepatitis C cocktail drug fails a 4-week challenge. Report

CRO News

> India's GVK snags an early-stage CRO amid global growth. News

> Charles River deepens its ties to Huntington's R&D with new deal. Item

> FDA taps Icon to help patients better weigh in on trials. Story

> PPD dives into adaptive trials with Medidata deal. Report

> AMRI tanks on disappointing sales and a dimmer outlook. Article

Biotech IT News

> Google steps up Genomics pitch with $25-a-genome storage service. More

> Team taps Wikipedia for flu forecasting data. Story

> Open-source atlas of the human proteome goes live. Article

> FDA resumes its long search for a CIO. More

> AstraZeneca strikes $150M deal to buy data analysis business. Report

Animal Health News

> Jaguar postpones IPO amid rocky market for biotech and animal health offerings. Article

> Merck to meat industry: Zilmax is safe. Item

> FDA tightens reins on equine compounding companies. Report

> MWI shares sink despite better-than-expected earnings. Story

> Zoetis beats estimates on strength of livestock products and allergy drug for dogs. News

And Finally ... Insurer Cigna ($CI), facing discrimination allegations, has agreed to restructure HIV drug benefits. More (sub. req.)

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.